Status:
COMPLETED
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrea...
Eligibility Criteria
Inclusion
- proteinuria greater than 1 gram/day serum creatinine \< 2.6 for men, \< 2.0 for women
Exclusion
- blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00240019
Start Date
December 1 2003
End Date
April 1 2006
Last Update
October 17 2006
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente of Northern California, Santa Clara and San Jose
Santa Clara, California, United States, 95051
2
Stanford University Medical Center
Stanford, California, United States, 94305